TARA Protara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TARA

Price (delayed)

$3.54

Market cap

$209.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$194.87M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in ...

Highlights
The debt has decreased by 30% YoY and by 10% from the previous quarter
The EPS has increased by 13% year-on-year
The equity rose by 12% year-on-year but it has declined by 11% since the previous quarter
The company's net income fell by 38% YoY and by 11% QoQ
Protara Therapeutics's quick ratio has decreased by 30% from the previous quarter and by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protaratx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TARA

TARA stock price

How has the Protara Therapeutics stock price performed over time
Intraday
-3.8%
1 week
-2.21%
1 month
-8.05%
1 year
-1.12%
YTD
-33.58%
QTD
-7.33%

Financial performance

How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$76.79M
Net income
-$70.02M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 38% YoY and by 11% QoQ
TARA's operating income is down by 34% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does TARA's price correlate with its fundamentals

Growth

What is Protara Therapeutics's growth rate over time

Valuation

What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
1.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 13% year-on-year
TARA's P/B is 113% above its 5-year quarterly average of 0.6
The equity rose by 12% year-on-year but it has declined by 11% since the previous quarter

Efficiency

How efficient is Protara Therapeutics business performance
TARA's return on invested capital is up by 44% year-on-year but it is down by 5% since the previous quarter
The ROA has contracted by 15% YoY and by 8% from the previous quarter
TARA's ROE is down by 13% year-on-year and by 8% since the previous quarter

Dividends

What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TARA.

Financial health

How did Protara Therapeutics financials performed over time
The total liabilities is up by 38% since the previous quarter and by 18% year-on-year
Protara Therapeutics's current ratio has decreased by 30% from the previous quarter and by 14% YoY
The debt is 98% less than the equity
Protara Therapeutics's debt to equity has decreased by 33% YoY
The debt has decreased by 30% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.